XOMA (XOMA)
(Delayed Data from NSDQ)
$25.79 USD
+0.55 (2.18%)
Updated May 31, 2024 04:00 PM ET
After-Market: $25.92 +0.13 (0.50%) 6:18 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 321 - 330 ( 330 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2011 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials: Cash Runway Through Major Clinical Value Drivers.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials a Nonevent. We See Cash Runway Through Important Clinical Data in Q1:11. Fair Value Moves to $1.30.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials Preview, Model Update, and Business Outlook.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences: Biopharmaceuticals / Biotechnology.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials Uneventful. Value Driving Clinical Data Releases Expected in Q4:10 and Q1:11.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials Preview, Model Update, and Business Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2009 Financials were Uneventful. 2010 Milestones Include Important Clinical Data and a Potential Partnership
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L